



The 73rd Shareholders' Newsletter

From April 1, 2025 to
March 31, 2026

Securities code: 8086



We are pleased to present the Shareholders' Newsletter for the 73rd business year (April 1, 2025 to March 31, 2026), and kindly invite you to review the information provided.

President and Representative Director Yamazaki Tsuyoshi


I would like to express my sincere gratitude to our shareholders for your continued support. Guided by our corporate creed of "Willingness," we have pursued management aimed at creating value for society by providing products and services from the patients' perspective, while embracing the spirit of "Sanpo-yoshi" and maintaining users' viewpoints.

In FY2025, we focused on improving profitability and capital efficiency through organizational restructuring, operational reviews, and the consolidation of product lines, steadily laying the foundation for further enhancement of corporate value. As a result, operating profit exceeded the target of 37 billion yen, and both consolidated net sales and operating profit reached record highs.

Building on these initiatives and under our FY2026 management policy "Make it happen!" we will further enhance our execution and achieve greater corporate value and sustainable growth.

Through the creation and innovation of products, technologies, and businesses that support the health of people around the world and address their medical needs, we will contribute to society as "a truly global comprehensive healthcare company with a spirit of WA-gokoro." We sincerely appreciate your continued support.

Consolidated Financial Highlights



Overview by Segment




Medical-related


Net sales **523,615** million yen

3.7% up Y o Y

Percentage of net sales



Net sales trends (million yen) Half year Full year




Pharmaceutical-related


Net sales **81,107** million yen

2.5% up Y o Y

Percentage of net sales



Net sales trends (million yen) Half year Full year




PharmaPackaging


Net sales **54,687** million yen

7.7% down Y o Y

Percentage of net sales



Net sales trends (million yen) Half year Full year



Other

Net sales **1,128** million yen

0.8% up Y o Y


Percentage of net sales by region

Europe **14.9%**

Americas **20.1%**

Asia **16.4%**

Japan **48.6%**



NIPRO new information

Notice Regarding Submission of an Application for Full Approval of the Regenerative Medicine Product “STEMIRAC® Injection”



We have resubmitted an application to the Ministry of Health, Labour and Welfare for full approval of “STEMIRAC® Injection,” a regenerative medicine product jointly developed with Sapporo Medical University. STEMIRAC® Injection received conditional and time-limited approval on December 28, 2018, with an indication for improving neurological symptoms and functional impairment associated with spinal cord injury. Based on this conditional and time-limited approval, we conducted a post-marketing evaluation and verified the product’s efficacy and safety internally within the seven-year approval period. Accordingly, we have now resubmitted this application for full approval.

Notice Regarding a Clinical Trial of the nOCT Imaging System in the U.S.

We are pleased to announce the enrollment of the first patient in the INSYTE trial, a clinical trial for the world’s first*1 nOCT Imaging System*2 being developed in the U.S. by Spryte Medical, our consolidated subsidiary headquartered in Massachusetts, USA. This clinical trial received an Investigational Device Exemption (IDE)*3 from the U.S. Food and Drug Administration (FDA) in November last year. This system is intended to provide high-resolution visualization during treatment of intracranial vascular conditions that have previously been difficult to assess during cerebral aneurysm treatment and follow-up procedures, and to evaluate its safety and effectiveness in supporting treatment. Furthermore, this is the first clinical trial approved by the U.S. Food and Drug Administration (FDA) for an intravascular optical imaging system specifically designed for the cerebrovascular field.



First patient enrolled in the INSYTE trial at Baptist Health Jacksonville, U.S.

This system is a medical device currently in the research and development stage and has not yet received FDA approval or clearance. This trial is intended to evaluate the potential for future clinical application.

*1 Reference: Science, May 15, 2024 (American Association for the Advancement of Science [AAAS])

*2 Neuro Optical Coherence Tomography (nOCT) Imaging System: An imaging technology based on optical coherence tomography (OCT) capable of high-resolution visualization within cerebral blood vessels

*3 IDE (Investigational Device Exemption): An FDA authorization that permits the conduct of clinical trials for a medical device in preparation for a future approval application

Shareholder Memo

Fiscal year From April 1 of each year to March 31 of the following year

Record date for determining shareholders Annual General Meeting of Shareholders March 31
Year-end dividend March 31
Interim dividend September 30

Number of shares per unit 100 shares

Method of public notice Electronic public notice <https://www.nipro.co.jp/en/>
In the event that it is impossible to provide an electronic public notice due to an accident or other unavoidable circumstances, the notice will be published in the Nihon Keizai Shimbun.

Shareholder register administrator Mizuho Trust & Banking Co., Ltd.,
1-3-3 Marunouchi, Chiyoda-ku,
Tokyo 100-8241, Japan

Location of administrative handling Mizuho Trust & Banking Co., Ltd.
Head Office, Stock Transfer Agency Department,
1-3-3 Marunouchi, Chiyoda-ku, Tokyo 100-8241, Japan

Contact point Securities company, etc. with which you do business
In the case of a special account, the relevant branch office of the special account management institution

Special account management institution Mizuho Trust & Banking

Relevant branch office Toll free 0120-288-324
(9:00~17:00 excluding Saturdays, Sundays, and national holidays)

Payment of unpaid dividends Mizuho Trust & Banking Co., Ltd. and Mizuho Bank, Ltd.

For inquiries about the electronic provision of materials for the general meeting of shareholders (request for paper delivery), please contact your securities company or the Mizuho Trust & Banking electronic provision system hotline. (For special accounts, please contact the Mizuho Trust & Banking electronic provision system hotline.) Mizuho Trust & Banking electronic provision system hotline 0120-524-324 (9:00~17:00 excluding Saturdays, Sundays, and national holidays)

Shareholder Benefit Program

To express our sincere gratitude to our shareholders for their ongoing support, we have established a shareholder benefit program. JCB Gift Cards will be presented based on the number of shares held and the period of holding.

* For details about the continuous holding period and other information, please refer to our website.

NIPRO Official Instagram Account

The NIPRO official Instagram account is used to share various information from within and outside Japan. Please follow and like our posts!

Account information

NIPRO Group Official/
[Official]
NIPRO Corporation
Username: [wearenipro](#)

